Introduction
Methods
Surgical Therapy
Noninvasive Therapy
Energy-Based Interventions
Lasers
CO2 Laser
Type of study | N and inclusion criteria | Design | Outcome | Adverse events | Study |
---|---|---|---|---|---|
Controlled comparative study | 92 Pre- and post-menopausal with GSM or dyspareunia | Study group: (n=40) PRP, laser, PF exercises Control group: (n=52) PRP, PF exercises 3 Txs, 1 Tx every 30 days Evaluated 30 days after last Tx Vaginal Bx pre-Tx and 30 days after Tx Sexual questionnaire | Sexual questionnaire with improvement in discomfort with sex Vaginal biopsies showed increased fibroblasts, neoangiogenesis, increased thickness of vaginal epithelium and glycogenic property Improvement in GSM symptoms | Minimal vaginal bleeding Mild discomfort during Tx | Gaspar et al. [20•] |
Randomized control trial, double-blinded placebo control | 45 Post-menopausal with GSM | (n = 15) Laser + sham vaginal estrogen (n = 15) laser + vaginal estrogen (n = 15) vaginal estrogen + sham laser Follow-up at 8 and 20 weeks VHI, FSFI | VHI was improved in all groups Laser and laser + estrogen showed improvement in dyspareunia, burning, and dryness Estrogen alone only showed improvement in dryness FSFI improved in laser + estrogen group | Dyspareunia with laser alone | Cruz et al. [14•] |
Prospective cohort | 50 Post-menopausal with GSM and dissatisfied with vaginal estrogen | 3 Txs over 12 weeks Evaluated at 12-week follow-up VAS, VHI, SF-12, satisfaction | VAS improved VHI improved QOL improved on SF-12 84% satisfied with Tx | None | Salvatore et al. [23] |
Prospective cohort | 77 Post-menopausal with GSM | 3 Txs of laser over 12 weeks Evaluated 12 weeks post-Tx VAS, VHI, SF-12 | VAS improved VHI improved QOL improved on SF-12 | None | Salvatore et al. [24] |
Prospective cohort | 48 Post-menopausal with GSM, failed vaginal estrogen | 3 Txs over 30 days Evaluated 30 days post-Tx VHI, VAS, satisfaction | VHI improvement VAS improvement 91% satisfaction | None | Perino et al [22]. |
Prospective cohort | 50 Post-menopausal with GSM | 1 Tx Biopsies of vaginal tissue pre-Tx, and 2 months after Tx VHI | Improvement in VHI, improvement in GSM increased vaginal epithelial thickness and glycogen and increased fibroblast activation | None | Zerbinati et al. [21] |
Prospective cohort | 50 Hx of breast cancer and oncological menopause with GSM | 3 Txs Evaluated 30 days post-Tx VHI, VAS | VHI improvement VAS improvement | Pain with probe insertion | Pieralli et al [7]. |
Randomized control trial Single-blinded | 62 Post-menopausal with GSM | Study group: (n=30) laser, 3 Txs over 6 weeks Control group: (n=32) vaginal estrogen, Tx for 24 weeks Evaluated 6 months post-Tx VAS, VHI, FSFI, DIVA, UDI-6, VMI, PGI-I | Laser Tx and vaginal estrogen similar improvements in GSM, urinary symptoms and sexual function, and satisfaction | None | Paraiso et al [37•]. |
Prospective cohort | 140 Post-menopausal with GSM | 3 Txs Q month FSFI, SF-12, VHI, ICIQ | Improvement in sexual arousal, sexual satisfaction, urinary symptoms, vaginal dryness, itching, and dyspareunia | Adabi et al [38]. | |
Prospective cohort | 84 Pre-menopausal women with VL and decreased sensation during intercourse | 3 Txs Q month Evaluated 3 months and 6 months post-Tx VHI, FSFI | VHI and FSFI were improved at 3 months post-Tx, and decreased by 6 months post-Tx | Lauterbach et al [39]. | |
Prospective cohort study | 43 Patients with vaginal shortening, atrophy, and stenosis following RT for gynecologic cancer | 3 Txs Q month Follow-up at 6 months Vaginal length, VHI, FSFI | Improvement in vaginal length, and VHI No changes in FSFI | Perrone et al [40]. | |
Randomized control trial | 50 Post-menopausal with VVA | Study group: (n = 25) 3 Txs, Q month for 3 months Control: (n = 25) vaginal estrogen 3 days per week for 3 months Evaluated 3 months post-Tx VHI, FSFI | VHI improvement in both groups, no difference between the two groups FSFI improvement in both groups, more improvement in laser group for arousal, satisfaction, desire, and dyspareunia | Eftekhar et al [41•]. | |
Prospective cohort study | 52 Pre-menopausal and post-menopausal with vaginal dryness | 3 Txs Q month Vaginal smears obtained pre- and post-Tx Evaluated vaginal cytology and VAS | VAS improved in both pre- and post-menopausal groups No significant difference in parabasal, intermediary and superficial cells | Takacs et al [42]. | |
Randomized control trial double-blinded sham-controlled | 88 Post-menopausal with VVA | Study group (n=44) Q month Tx with CO2 laser 3 Txs Control group (n=44) Q month Txz x 3 with sham Participants and evaluators were blinded Evaluated 12 weeks after Tx VHI, VAS, ICIQ-VS, satisfaction | VHI, VAS, and vaginal dryness were improved ICIQ-VS no difference Study group more satisfied with Tx | No difference in adverse events | Ruanphoo et al [43•]. |
Erbium:Yttrium-Aluminum-Garnet
Type of study | N and inclusion criteria | Design | Outcome | Adverse events | Study |
---|---|---|---|---|---|
Pilot study | 135 VL | 1 Tx Evaluated at 1, 3, 6 months | 90.4% reported satisfaction with vaginal tightening improvement | No | Rivera [25] |
Pilot study | 17 | 1 Tx PISQ-12 Evaluated at 1 month and 3 months after treatment | PISQ-12 improvement | Mild burns (n = 1) | Fistonic [45] |
Pilot study | 21 VL | 2 Txs, Q 15 days to 1 month Evaluation at 3 months post-Tx LVT, POP-Q, PISQ-12, satisfaction | 95% reported strong or moderate improvement in vaginal tightness, all partners reported improved tightness, 85% reported improved sensation Improvement in POP-Q No change in PISQ-12 | None | Gaviria et al [26]. |
Prospective comparative cohort study | 70 Post-menopausal with GSM Cohort with SUI | Laser group: (n=45) 1 Tx Er:YAG laser Q month for 3 months Control group: (n=25) 1g vaginal estrogen or 50mg of estriol twice weekly for 3 months Evaluated at 3 & 6 months VAS, VHI N= 19 with incontinence studied pre- and post-Tx with SUI ICIQ-UI SF | VAS improved in both groups, more improved in laser VHI improved in both groups, more improved in laser Improved ICIQ-SF | Mild discomfort with treatment | Gambacciani et al [19]. |
Retrospective cohort | 60 Patient that underwent laser therapy | Telephone interviews using LVT | Average duration of effect was 16 months Improvement in SUI and prolapse 83% would repeat the therapy | Mild edema Tolerable heating sensation | Gaviria et al [46]. |
Prospective cohort study | 98 SUI | 2 Txs Q month Laser applied to anterior vaginal wall and urethral vestibule, biopsy of vaginal tissue pre- and post-treatment Evaluation 2 months post-Tx | Increase in density of blood capillaries and thickness of the epithelial layer increased fibroblasts | Lapii [44] | |
Prospective comparative cohort study | 50 GSM | Study group: Er:YAG laser 2 Txs and vaginal estrogen Control group: vaginal estrogen Biopsies taken at 1, 3, 6, 12 months Evaluated at 12 months VAS, VMI | Improved VAS in both groups, more pronounced in the laser group Histology showed angiogenesis, congestion and restricting of the lamina propria in the laser group | Laser group = 4%, estriol group = 12% | Gaspar [47•] |
Prospective cohort | 24 Post-menopausal with history of breast cancer and GSM | 3 Txs, Q month SPEQ, VHI | Improved SPEQ and VHI | Areas et al. [48] | |
Prospective cohort | 33 | 2 Txs, Q month Evaluation at 4, 2, 6 months post-treatment ICIQ-SF QOL Likert scale | Significant improvement in QOL, improvement in ICIQ-SF | Vaginal discharge, spotting, burning; all transient | Reisenauer [49] |
Radiofrequency Therapy
Device | Type of study | N and inclusion criteria | Design | Outcome | Adverse events | Study |
---|---|---|---|---|---|---|
Transmucosal controlled radiofrequency heating device | Double-blinded randomized control trial | 20 Post-menopausal with SUI on positive CST and VL | Study group: (n=10) laser Control group (n=10) sham 3 Txs Q month Evaluated at 3 months SUI assessment UDI-6 , ICIQ-UI SF, cough stress test VHI, VAS Biopsies at urethra vesical junction and of the vulva pre- and post-Tx | UDI-6 improvement, ICIQ-UI SF improvement and 70% had a negative cough stress test VHI and VAS Histology showed increased collagen | None | Leibaschoff et al [52•]. |
Prospective cohort study | 25 Pre- and post-menopausal women with difficulty achieving orgasm | 3 Txs Q month Survey | 23/25 reported reduction in time to orgasm, improved vaginal tightening, improved dryness and clitoral sensitivity | None | Alinsod et al [53]. | |
Cryogen-cooled monopolar radiofrequency | Prospective cohort study | 24 Pre-menopausal with VL | 1 Tx Evaluated at 6 months Self-reported vaginal tightness FSFI, FSDS-R, sexual satisfaction | Vaginal tightness improvement in 67% Improved FSFI, FSDS-R improved, improvements in sexual satisfaction | None | Millheiser et al [27]. |
Prospective cohort study | 30 Pre-menopausal with VL | 1 Tx Evaluated at 12 months FSFI, FSDS-R, VL questionnaire, sexual satisfaction questionnaire | FSFI improved FSDS-R improved improved vaginal laxity, improved sexual satisfaction | None | Sekiguchi et al [28]. | |
Randomized placebo sham-controlled, blinded study | 174 Pre-menopausal with VL | Study group: (n=117) 1 laser Tx Control group: (n=57) 1 sham Tx Evaluated at 6 months VLQ, FSFI | VLQ score and FSFI improved more in RF group compared to the sham | Krychman et al [57•]. | ||
Randomized control trial | 35 SUI | Group 1: (n = 21) 1 CMRF Tx Group 2: (n = 14) 2 CMRF Tx Evaluated at 1, 4, 6, and 12 months post-Tx UDI-6, ILQ-7, ICIQ-UI-SF, pad weights | Both groups had improved pad weights and SUI symptoms and QOL 80% reported less leakage episodes | 1 pt reported UTI | Allan et al [58•]. | |
Bipolar radiofrequency | Prospective cohort | 14 Post-menopausal with GSM | 3 Txs WHOQOL questionnaire, FSFI, ICIQ-VS Satisfaction | WHOQOL showed improvement in health FSFI improvement in most categories ICIQ-VS Improvement in all 100% report satisfaction | Kamilos et al [54]. | |
Prospective cohort | 30 VL symptoms | 1 Tx Evaluated 2 months post-Tx ICIQ-VS, PFIQ-7, IIQ-7, ICIQ-UISF | Improvement in vaginal laxity, sexual symptoms QOL, and SUI | None | Caruth [55] | |
Prospective cohort | 55 Post-menopausal with GSM | 3 Txs Vaginal smears were obtained during the treatments, VHI | Increase in lactobacillus, decrease in vaginal pH, increase in parabasal cells and superficial cells; VHI improved | Sarmento et al [59]. | ||
Monopolar radiofrequency | Prospective cohort | 17 Pre- and post-menopausal with labial laxity | 4 Txs weekly FSFI, VAS | Improved FSFI Improved VAS | Mild discomfort during Tx | Fistonic et al [45]. |
Prospective cohort | 27 SUI and VL | 3 Txs, Q week ICIQ-UISF VVLQ | 100% report improved VL 89% report improved SUI 93% report improved sexual satisfaction | None | Lalji et al [56]. | |
Prospective cohort | 19 | 4 Txs weekly Images at baseline and 1month Evaluated vulvar appearance at 12 months, FSFI | Moderate change in vulvar appearance and laxity FSFI improved | Clark [51] |